Semasize 0.25 mg may be used for:

• Management of type 2 diabetes mellitus along with diet and exercise

• Chronic weight management as an adjunct to a reduced-calorie diet and increased physical activity

The doctor will decide the appropriate indication, dose and duration of treatment.

Semasize 0.25 mg contains semaglutide, which mimics the action of GLP-1, a naturally occurring hormone involved in blood glucose and appetite regulation.

It increases insulin release when blood glucose is elevated and reduces glucagon release. It also slows gastric emptying and can reduce appetite. Together, these effects help improve blood glucose control and support weight management when combined with appropriate diet and physical activity.

Tell your doctor about all medicines you take before starting Semasize 0.25 mg.

• Insulin or sulfonylureas: Using semaglutide with these medicines can increase the risk of low blood sugar. Your doctor may adjust their doses.

• Oral medicines: Semaglutide delays gastric emptying and may affect the absorption of some oral medicines.

• Warfarin or other coumarin medicines: Closer monitoring of blood clotting may be required when semaglutide treatment is started.

• Other semaglutide-containing medicines or GLP-1 receptor agonists: Do not combine them with Semasize unless specifically advised by your doctor.

• Store Semasize 0.25 mg in a refrigerator at 2°C to 8°C.

• Do not freeze.

• Keep it out of the reach of children.

• Keep the medicine protected from light.

• Follow the storage instructions on the product packaging and do not use the medicine if it has been frozen.

• Semasize 0.25 mg is given as a subcutaneous injection, meaning it is injected under the skin.

• It is generally administered once a week, on the same day each week, as prescribed by your doctor.

• It can be injected into the abdomen, thigh or upper arm.

• The 0.25 mg dose is generally used during the initial phase of semaglutide treatment to help the body adjust to the medicine. Your doctor may increase the dose gradually depending on your response and tolerability.

• The prefilled syringe is intended for single use. Do not reuse or share it.

• Semasize can generally be administered with or without food.

• Use only the dose prescribed by your doctor. Do not change the dose or frequency on your own.

Semasize 0.25 mg can cause gastrointestinal side effects, particularly during the early stages of treatment.

Common side effects

• Nausea

• Vomiting

• Diarrhoea

• Constipation

• Abdominal pain

• Indigestion

• Decreased appetite

• Headache

• Dizziness

Serious side effects

Contact your doctor promptly if you develop severe or persistent symptoms such as:

• Severe, persistent abdominal pain, which may indicate pancreatitis

• Persistent vomiting or diarrhoea with signs of dehydration

• Symptoms of low blood sugar, especially when used with insulin or sulfonylureas

• Sudden changes in vision

• Symptoms of a serious allergic reaction, such as swelling of the face or throat or difficulty breathing

• Symptoms suggesting gallbladder problems, such as severe upper abdominal pain

• Use Semasize exactly as prescribed by your doctor.

• The 0.25 mg dose is generally used at the beginning of treatment. Do not increase the dose yourself.

• Take your injection on the same day each week to maintain a consistent routine.

• Rotate injection sites between the abdomen, thigh and upper arm.

• Do not inject Semasize into a vein or muscle.

• The prefilled syringe is for single use only. Do not reuse or share it.

• Drink enough fluids, particularly if you experience vomiting or diarrhoea.

• Tell your doctor if you are taking insulin or a sulfonylurea because the risk of low blood sugar may increase.

• Inform your doctor if you have a history of pancreatitis, gallbladder problems, severe stomach-emptying problems or diabetic eye disease.

• If you are planning a pregnancy, discuss stopping Semasize with your doctor at least 2 months beforehand.